Update on COVID-19 Treatment: A triple combination antiviral therapy shows favourable results in a Phase-2 randomised clinical trial.

In an open label, randomised, phase 2 clinical trial, triple combination of interferon beta-1b (an injectable interferon), lopinavir–ritonavir (oral protease inhibitor) and ribavirin (oral nucleoside analogue) were shown safe and superior to monotherapy with lopinavir‑ritonavir. This triple combination shown efficacy in shortening virus shedding, alleviating symptoms, and facilitating discharge of COVID-19 patients with mild to

error: Content is protected !!